1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says
By Chris Villani ( March 21, 2019, 6:36 PM EDT) -- Allergan PLC said a group that claims the company's anti-competitive methods caused it to overpay for its ulcerative colitis drug should not get a second chance at class certification after the First Circuit knocked down its first attempt....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.